Mast Therapeutics, Inc. (MSTX)

[Pian0wire]

Yes, MSTX is in an oversold position. The failure of the Phase III trial is a tough one, but they have other promising things in the pipeline. I listened to the conference call last night, and they still will have over 25 million in cash AFTER they put $10 million toward the current debt. They stated that was their plan. Not bad if you ask me. This is oversold. Do yourselfs a favor and listen to the conference call.